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OBJECTIVES This study sought to compare aggregate medical care costs for patients undergoing
percutaneous coronary intervention with paclitaxel-eluting stents (PES) and bare-metal stents
(BMS) and to formally evaluate the incremental cost effectiveness of PES for patients
undergoing single-vessel percutaneous coronary intervention.
BACKGROUND Although the cost effectiveness of SES has been studied in both clinical trials and
decision-analytic models, few data exist on the cost effectiveness of alternative drug-eluting
stent (DES) designs. In addition, no clinical trials have specifically examined the cost
effectiveness of DES among patients managed without mandatory angiographic follow-up.
METHODS We performed a prospective economic evaluation among 1,314 patients undergoing percu-
taneous coronary revascularization randomized to either PES (N  662) or BMS (N  652)
in the TAXUS-IV trial. Clinical outcomes, resource use, and costs (from a societal
perspective) were assessed prospectively for all patients over a 1-year follow-up period. Cost
effectiveness was defined as the incremental cost per target vessel revascularization (TVR)
event avoided and was analyzed separately among cohorts assigned to mandatory angio-
graphic follow-up (n  732) or clinical follow-up alone (n  582).
RESULTS The PES reduced TVR by 12.2 events per 100 patients treated, resulting in a 1-year cost
difference of $572 per patient with incremental cost-effectiveness ratios of $4,678 per TVR
avoided and $47,798/quality-adjusted life year (QALY) gained. Among patients assigned to
clinical follow-up alone, the net 1-year cost difference was $97 per patient with cost-
effectiveness ratios of $760 per TVR event avoided and $5,105/QALY gained.
CONCLUSIONS In the TAXUS-IV trial, treatment with PES led to substantial reductions in the need for
repeat revascularization while increasing 1-year costs only modestly. The cost-effectiveness
ratio for PES in the study population compares reasonably with that for other treatments that
reduce coronary restenosis, including alternative drug-eluting stent platforms. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.063Cardiol 2006;48:253–61) © 2006 by the American College of Cardiology Foundation
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fver the past 5 years, both sirolimus-eluting stents (SES)
nd paclitaxel-eluting stents (PES) have been shown to
See page 268
ubstantially reduce rates of angiographic and clinical reste-
osis after percutaneous coronary intervention (PCI) com-
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ccepted February 28, 2006.ared with conventional bare-metal stents (BMS) (1–3). In
ddition to improved clinical outcomes, economic analyses
ased on both decision-analytic models as well as patient-
evel data from clinical trials have shown that drug-eluting
tents (DES) are reasonably cost effective compared with
ther generally accepted medical interventions, at least for
atients at moderate to high risk of restenosis after single-
essel PCI (4,5). Based on these data, most third-party
ayers, including the Center for Medicare and Medicaid
ervices, have provided incremental reimbursement for
ES, and these devices have been rapidly incorporated into
tandard clinical practice.
Nonetheless, several important questions regarding the
ost effectiveness of DES remain unanswered. First, all of
he published economic analyses to date are based on data
or SES. Whether these analyses apply similarly to PES is
nknown. Moreover, the data derived from the SES trials
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estenosis in the control arms of these trials were somewhat
igher than previous reports would have suggested (6,7). To
ome extent, this increase may relate to selection of patients
t higher-than-average risk of restenosis for inclusion in the
tudy (2,8). More importantly, however, the vast majority of
atients in these studies were assigned to undergo manda-
ory angiographic follow-up—a process that is known to
ncrease the need for repeat revascularization compared with
linical follow-up alone (9,10). Thus, the extent to which
ES reduce the need for follow-up cardiovascular proce-
ures and costs among patients in routine clinical practice is
nknown.
To address these unresolved issues, we performed a
rospective economic substudy as part of the randomized
AXUS-IV trial. The goals of the study were: 1) to define
he net 1-year cost of care for patients undergoing PCI with
ither PES or conventional BMS; 2) to formally evaluate
he cost effectiveness of PES versus BMS for patients
ndergoing single-vessel PCI, from a societal perspective;
nd 3) to examine the impact of mandatory angiographic
ollow-up versus clinical follow-up alone on the cost effec-
iveness of PES.
ETHODS
atient population and treatment protocol. Between
arch 29 and July 8, 2002, 1,314 patients undergoing PCI
ere enrolled in the TAXUS-IV trial at 73 U.S. centers.
etails of the study design have been described previously (3).
riefly, patients were eligible if they were undergoing planned
CI to a de novo lesion 10 to 28 mm in length, located in a
ative coronary artery with a reference vessel diameter 2.5 to
.75 mm (by visual estimate). Patients who required con-
urrent PCI of a lesion in a vessel separate from the study
esion were allowed to be enrolled after successful treatment
f the nontarget lesion with an approved BMS. The study
rotocol was approved by the institutional review board at
ach site, and each patient provided informed consent
efore enrollment.
Patients were randomized in a double-blind fashion to
mplantation of either the slow-release, polymer-based PES
Abbreviations and Acronyms
BMS  bare-metal stent
CI  confidence interval
DES  drug-eluting stent
DRG  diagnosis-related group
ICU  intensive care unit
PCI  percutaneous coronary intervention
PES  paclitaxel-eluting stent
QALY  quality-adjusted life year
SES  sirolimus-eluting stent
TVR  target vessel revascularizationTaxus, Boston Scientific, Natick, Massachusetts; n  662) hr a visually indistinguishable BMS (Express, Boston Sci-
ntific, n  652) stratified by clinical site, target vessel
iameter (3.0 vs. 3.0 mm), and the presence of diabetes
ellitus. Stent implantation was performed using standard
echniques. Postprocedure, all patients received aspirin in-
efinitely and clopidogrel (300 mg loading dose followed by
5 mg daily) for at least 6 months. At the time of study
nrollment, patients were assigned to either mandatory
ngiographic follow-up at 9 months (n  732) or clinical
ollow-up alone (n  582).
Case report forms documenting baseline patient charac-
eristics, procedural details (including resource use), and
linical outcomes during the initial hospitalization and
-year follow-up period were completed by a trained re-
earch coordinator. All end points (death, myocardial in-
arction, repeat revascularization) were reviewed by an
ndependent clinical events committee who was blinded to
reatment assignment. Repeat revascularization was consid-
red clinically driven if there was evidence of active myo-
ardial ischemia by symptoms, provocative testing, or both.
etermination of medical care costs. The primary ana-
ytic perspective of our study was societal, consistent with
uidelines from the U.S. Panel on Cost Effectiveness in
ealth and Medicine (11). For this analysis, medical care
osts for the initial hospitalization and the 1-year follow-up
eriod were estimated using a combination of resource-
ased costs and hospital billing data as previously described
12,13). Although some studies have used diagnosis-related
roup (DRG) payments as a proxy for cost from a societal
erspective, we thought that in the case of a relatively new
rocedure such as DES, a more detailed approach that
pecifically accounted for variability in procedural as well as
ospital resource utilization would more accurately repre-
ent opportunity cost.
ARDIAC CATHETERIZATION LABORATORY COSTS. De-
ailed resource use was recorded for each procedure, and the
ost of each item was estimated on the basis of the mean
ospital acquisition cost for the item in 2004. The costs of
MS and PES were set at $800 and $2,700 per stent,
espectively, based on average hospital acquisition costs for
ach as of April 2004 (when PES were approved for
ommercial sale in the U.S.) (14). Costs of additional
upplies, overhead, and depreciation for the cardiac cathe-
erization laboratory and nonphysician personnel were esti-
ated on the basis of the average cost per procedure at Beth
srael Deaconess Medical Center in 2004 and adjusted for
ctual procedure duration.
THER HOSPITAL COSTS. All other hospital costs were
stimated using hospital billing data and department-level
ost-to-charge ratios as previously described (13). For 460
andomly selected patients, itemized bills were obtained for
he initial hospitalization and any subsequent cardiovascular
ospitalizations during follow-up. Hospital costs were then
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ost-center specific cost-to-charge ratio obtained from the
ospital’s Medicare cost report. Previous studies from our
roup and others have shown this method to correlate well
ith data from detailed cost-accounting systems, particu-
arly for the purposes of group comparisons (13,15). All
osts were converted to 2004 dollars based on the medical
are component of the consumer price index.
For the remaining patients, nonprocedural hospital costs
ere estimated based on a linear regression model developed
sing the hospital admissions for which complete billing
nformation was available. Independent variables for this
odel included length of stay, intensive care unit (ICU)
ength of stay, bleeding complications, and revascularization
rocedures. For the purposes of our study, only those target
essel revascularization (TVR) procedures that were deter-
ined by the clinical events committee to have been
linically driven were included in the economic analysis so as
o limit contamination by angiographically driven proce-
ures or revascularization events unrelated to the study
tent.
THER COSTS. Physician services for inpatient procedures
nd daily care were assigned costs based on the Medicare fee
chedule. Outpatient services and medications (with the
xception of thienopyridine treatment) were not tracked
uring the study and were therefore excluded from the
conomic analysis. Although both treatment groups re-
eived 6 months of clopidogrel, the primary analysis as-
igned patients in the control group a cost for only 1 month
f clopidogrel to reflect as closely as possible standard
ractice after BMS implantation at the time of the study.
THER ANALYTIC PERSPECTIVES. Secondary analyses were
erformed in which costs were assessed from both a hospital
erspective and a third-party payer (Medicare) perspective.
or the hospital perspective analysis, hospitalization-related
osts were assessed as previously described and were bal-
nced against mean Medicare reimbursement rates; all other
osts, including physician payments and outpatient medica-
ions, were excluded. For the analysis from the perspective
f the Medicare program, mean 2004 Medicare reimburse-
ent rates were assigned to each hospitalization based on
he underlying DRG as determined by an expert coder who
as blinded to treatment assignment. Physician costs were
ssigned using the 2004 Medicare fee schedule, and costs for
utpatient medications (including clopidogrel) were ex-
luded because outpatient medications were not covered by
edicare in 2004.
tatistical analysis. Discrete data are reported as frequen-
ies, and continuous data are reported as mean  SD. Cost
ata are reported as both mean and median values. Discrete
ariables were compared using the Fisher exact test. Nor-
ally distributed continuous variables were compared by the
tudent t test. Cost and other non-normally distributed data
length of stay, procedure duration) were compared by theilcoxon rank-sum test. Given their non-normal distribu- tions, confidence intervals for cost differences were esti-
ated using bootstrap resampling. All statistical analyses
nd cost-effectiveness analyses were performed according to
he intention-to-treat principle.
ost-effectiveness analyses. Because the major clinical
enefit of the PES was a reduction in the incidence of
linical restenosis requiring repeat revascularization, the
rimary end point for the cost-effectiveness analysis was the
ncremental cost per repeat revascularization event avoided
ver the 1-year follow-up period. This disease-specific
ost-effectiveness ratio was calculated by dividing the 1-year
ifference in mean medical care costs by the 1-year differ-
nce in the frequency of TVR between the PES and BMS
roups (5). The use of TVR events avoided in the denom-
nator of the cost-effectiveness ratio is based on previous
tudies, which have shown that patients who require TVR
ave an impaired quality of life over the first year of
ollow-up compared with patients who avoid such events
16,17).
We also performed a secondary cost-effectiveness analysis
sing the standard metric of cost per quality-adjusted life
ear (QALY) gained. Because quality of life was not
ssessed in the TAXUS-IV trial, quality-adjusted life ex-
ectancy for each patient was estimated on the basis of
revious data from the Stent-PAMI (Stent Primary Angio-
lasty in Myocardial Infarction) trial (18). In that study, the
uroQoL health status instrument was administered to 771
atients at 1, 6, and 12 months after initial revascularization,
nd population-level utilities were assigned to each patient
ased on a published regression model (19). Weighted
verages of utility values at the 3 time points were used to
stimate a mean quality-adjusted life expectancy for patients
ith and without repeat revascularization during follow-up
0.78 vs. 0.86, p  0.001), which were applied to the
AXUS-IV study population, along with a short-term
isutility “toll” for patients who required bypass surgery
20,21). As in previous cost-utility analyses (5,22), we
ssumed that there would be no differences in long-term
urvival or quality of life beyond the first year of follow-up,
ecause previous studies have shown no association between
oronary restenosis and long-term mortality (23). To esti-
ate the uncertainty surrounding cost-effectiveness ratios,
e calculated bias-corrected confidence intervals for each
ost-effectiveness ratio by the bootstrap method, using
,000 repeat samplings of the study population.
ensitivity and subgroup analyses. To estimate the cost
ffectiveness of PES in the real world without distortion by
rotocol-driven angiographic follow-up, we performed a
respecified analysis among the 582 patients assigned to
linical follow-up alone. Additional prespecified subgroup
nalyses were performed in which patients were stratified by
he presence or absence of treated diabetes mellitus and
ccording to vessel size and lesion length (as determined by
he angiographic core laboratory).
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atient population. For the overall study population, base-
ine clinical and angiographic characteristics were well
atched between the PES and BMS groups (Table 1).
he mean age was 62 years, and approximately 24% had
iabetes. By quantitative angiography, the mean lesion
ength was 13 mm; the mean reference vessel diameter
as 2.75 mm; and 32% of patients had reference vessel
iameters 2.5 mm.
nitial treatment costs and resource use. Table 2 summa-
izes resource use and costs for the index revascularization
rocedures. Not surprisingly (given the blinded nature of
he study), procedural resource use was virtually identical for
he two treatment groups. An average of 1.1 study stents
nd 0.3 nonstudy stents per patient were implanted for both
reatment groups, and 57% of patients received a glyco-
rotein IIb/IIIa receptor antagonist at the time of their
ndex procedure. The difference in initial procedural costs
as $1,988 (95% confidence interval [CI] $1,738 to $2,238)
nd was driven almost entirely by the higher acquisition cost
or PES compared with BMS. Similarly, there were no
Table 2. Procedural Resource Use and Cost
Paclita
(n
Procedure duration, min 51
Balloon catheters 2.9
Stents (all) 1.3
Stents (study) 1.1
Stents (nonstudy) 0.3
Glycoprotein IIb/IIIa inhibitor used
Resource costs
Medications $387 
Balloons/stents $3,966 
Additional procedural costs $1,972 
Total procedural cost $6,324 
able 1. Baseline Clinical and Angiographic Characteristics
Paclitaxel
Group
(n  662)
Control
Group
(n  652)
ge, yrs 63  11 62  11
ender, % male 71.8 72.4
iabetes mellitus, % 23.4 25.0
urrent smoker, % 23.4 20.1
revious myocardial infarction, % 30.5 29.9
ontarget vessel treated, % 19.8 17.0
jection fraction, % 55  10 55  10
ssigned to follow-up angiography, % 56.6 54.8
esion location
Left anterior descending, % 40.0 41.4
Circumflex, % 28.9 26.6
Right coronary artery, % 31.1 32.0
esion length (mm) 13.4  6.3 13.4  6.2
esion length 15 mm, % 30.5 30.6
eference diameter (mm) 2.75  0.47 2.75  0.49
eference diameter 2.5 mm, % 30.8 32.6
 NS for all comparisons.Values in brackets are medians.ignificant differences in initial hospital complications or
esource use between the 2 treatment groups (Table 3).
hus, total costs for the index hospitalization were $2,028
er patient higher for the PES group compared with the
ontrol group (95% CI $1,731 to $2,325).
ollow-up resource use and costs. Over the 1-year
ollow-up period, use of PES was associated with substantial
eductions in follow-up resource use and related health-care
osts (Table 4). In particular, the need for 1 or more repeat
VR procedures was reduced by 60% in the PES group
ompared with the BMS group (6.6% vs. 16.6%, p 
.001), with significant reductions in the need for bypass
urgery and repeat PCI procedures. The absolute reduction
n the number of TVR procedures performed during
ollow-up was 12.2 events per 100 patients treated (95% CI
.1 to 16.4).
In the overall study population, mean follow-up medical
are costs were $1,456 per patient lower in the paclitaxel
roup compared with the control group (95% CI $559 to
2,323) (Fig. 1). These cost savings were driven primarily by
eductions in the costs for repeat revascularization proce-
ures and their associated hospitalizations, but there were
odest reductions in physician fees as well. Mean 1-year
edical care costs for the PES group were $14,583, as
ompared with $14,011 for the control BMS group—a
ifference of $572 per patient (95% CI $346 less to $1,478
ore).
ost-effectiveness analyses. In our base case analysis, the
isease-specific incremental cost-effectiveness ratio was
4,678 per TVR avoided (Table 5). Bootstrap simulation
howed that this cost-effectiveness ratio remained
$10,000 per TVR avoided in 86.0% of simulations (Fig.
A). Our secondary analysis showed an incremental cost-
tility ratio of $47,798/QALY gained, with 14.8% of boot-
trap replicates showing economic dominance (i.e., lower costs
nd improved quality-adjusted life expectancy) and 56.8% of
he results $50,000/QALY gained (Table 5).
esults from the nonangiographic subgroup. Among the
respecified subgroup of patients assigned to clinical
ollow-up alone, use of PES was associated with an initial
roup
2)
Control Group
(n  652) p Value
51  28 0.94
4 2.8  2.4 0.46
7 1.3  0.8 0.70
3 1.1  0.3 0.81
7 0.3  0.8 0.76
57% 0.74
[$104] $442  1,853 [$104] 0.16
[$3,380] $1,924  1,193 [$1,440] 0.001
1,892] $1,969  426 [$1,814] 0.63
[$5,740] $4,336  2,427 [$3,852] 0.001xel G
 66
 27
 2.
 0.
 0.
 0.
58%
1,481
1,363
401 [$
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p
f
r
a
t
f
n
w
e
Q
t
p
a
7
A
a
s
s
r
a
e
(
e
d
w
p
t
t
w
$
t
a
P
d
p
T
D
M
R
R
N
H
H
F
T
A
V
257JACC Vol. 48, No. 2, 2006 Bakhai et al.
July 18, 2006:253–61 Cost Effectiveness of Paclitaxel-Eluting Stentsrocedural cost increase of $2,069/patient. At 1-year
ollow-up, randomization to PES was associated with a 62%
elative reduction in TVR (5.2% vs. 13.9%, p 0.001), with
n absolute reduction of 12.7 events per 100 patients
reated, and a corresponding $1,894 per patient reduction in
ollow-up costs (95% CI $538 to $3,275). Thus, the 1-year
et cost of PES versus BMS in the nonangiographic cohort
as $97 per patient, with an associated incremental cost-
ffectiveness ratio of $760 per TVR avoided and $5,105/
ALY gained (Table 5). Bootstrap simulation showed that
he disease-specific cost-effectiveness ratio was $10,000
er TVR event avoided in 90.0% of simulations (Fig. 2B),
nd the cost-utility ratio was $50,000/QALY gained in
6.3%.
dditional subgroup and sensitivity analyses. Stratified
nalyses according to additional patient characteristics are
ummarized in Figure 3. In general, these analyses were
imilar to the overall trial results, with cost-effectiveness
Table 3. Initial Hospital Events, Resource Use
Paclitax
(n 
Death, % 0
Myocardial infarction, % 2
Repeat PCI, % 0
Coronary artery bypass surgery, % 0
Diagnostic catheterization, % 1
Vascular complications, % 0
Transfusion, % 1
Length of stay, days 2.0  2.
Postprocedure length of stay, days 1.3  0.
Medical costs
Initial procedure $6,324  2,
Hospital room/ancillary/nursing $2,882  1,
Professional fees $1,889  34
Total $11,096  3,
Values in brackets are medians.
PCI  percutaneous coronary intervention.
able 4. Follow-Up Events, Resource Use, and Costs
Paclitaxel Group
(n  662)
eath, % 2.1
yocardial infarction, % 1.1
epeat TVR, % 6.6
CABG 1.7
PCI 5.1
epeat cardiovascular hospitalization, % 18.6
umber of TVR events (per 100 patients) 6.9
CABG 1.7
PCI 5.3
ospital admissions (per 100 patients) 26.4
ospital days (per 100 patients) 71.3
ollow-up costs
Hospitalizations $2,241 [$0]
Outpatient services/medications $814 [$540]
Physician fees $432 [$0]
otal follow-up costs $3,487 [$540]
ggregate 1-yr costs $14,583 [$11,699]alues in brackets are medians.
CABG  coronary artery bypass graft surgery; PCI  percutaneous coronary interventatios consistently $10,000 per repeat revascularization
voided. Paclitaxel-eluting stents were less attractive, how-
ver, for patients with reference vessel diameters 3.0 mm
C/E ratio $25,000 per TVR avoided), whereas they were
conomically dominant in patients with reference vessel
iameters 2.5 mm and in patients with diabetes mellitus.
The results of our analysis were substantially improved if
e assumed that all patients would receive 12 months of
ostprocedure clopidogrel treatment, regardless of stent
ype (Table 5). In the overall trial population, this assump-
ion reduced the 1-year cost difference from $572 to $122,
ith resulting cost-effectiveness and cost-utility ratios of
997 per TVR avoided and $10,183/QALY gained, respec-
ively. Among the subgroup assigned to clinical follow-up
lone, the assumption of equal clopidogrel duration changed
ES implantation from a cost-effective to an economically
ominant strategy, with 1-year cost savings of $353 per
atient compared with BMS implantation.
Costs
oup Control Group
(n  652) p Value
0.3 0.25
2.1 0.85
0.2 1.0
0.2 0.50
0.3 0.11
0.5 0.37
1.4 1.0
1.9  2.1 [1] 0.74
1.3  1.6 [1] 0.51
5,740] $4,336  2,427 [$3,852] 0.001
2,497] $2,849  1,960 [$2,497] 0.35
,749] $1,883  586 [$1,749] 0.18
10,165] $9,067  3,387 [$8,230] 0.001
Control Group
(n  652)
Difference
(95% Confidence Interval) p Value
1.4 0.7 (0.7 to 2.1) 0.40
2.5 1.4 (2.8 to 0.0) 0.06
16.6 9.9 (13.3 to 6.5) 0.001
3.8 2.2 (3.9 to 0.4) 0.02
13.3 8.2 (11.3 to 5.1) 0.001
26.4 7.8 (12.3 to 3.3) 0.001
19.2 12.2 (16.4 to 8.1) 0.001
3.8 2.2 (3.9 to 0.4) 0.02
15.3 10.0 (13.8 to 6.3) 0.001
38.0 11.6 (19.8 to 3.4) 0.01
104.9 33.6 (64.9 to 2.3) 0.03
$3,749 [$0] $1,508 (2,226 to 797) 0.001
$414 [$90] $400 (327 to 475) 0.001
$780 [$0] $349 (492 to 179) 0.001
$4,944 [$90] $1,456 (2,323 to 559) 0.001
$14,011 [$9,540] $572 (346 to 1,478) 0.001, and
el Gr
662)
.0
.4
.3
.0
.2
.2
.4
0 [1]
9 [1]
188 [$
858 [$
0 [$1
195 [$ion; TVR  target vessel revascularization.
i
p
a
e
r
r
o
s
M
f
d
h
t
$
D
T
P
p
u
$
p
c
p
F
g
c
a
le
5.
C
os
t
E
ffe
ct
iv
en
es
s
of
P
ac
lit
ax
el
-E
lu
tin
g
St
en
ts
U
nd
er
A
lte
rn
at
iv
e
A
ss
um
pt
io
ns
A
bo
ut
A
dj
un
ct
iv
e
M
ed
ic
at
io
ns
Sc
en
ar
io

C
os
t
(9
5%
C
I)
R
ep
R
ev
P
ro
ce
du
re
s
A
vo
id
ed
pe
r
10
0
P
at
ie
nt
s
C
/E
R
at
io
($
/R
ep
R
ev
A
vo
id
ed
)
%
<
$1
0,
00
0
pe
r
R
ep
R
ev
A
vo
id
ed
*
%
D
om
in
an
t*
C
/E
R
at
io
($
/Q
A
L
Y
G
ai
ne
d)
%
<
$5
0,
00
0/
Q
A
L
Y
G
ai
ne
d*
%
D
om
in
an
t*
ul
at
io
n:
ov
er
al
l
ri
m
ar
y
an
al
ys
is
†
$5
72
(
$3
46
to
$1
,4
78
)
12
.2
$4
,6
78
86
.0
14
.8
$4
7,
79
8
56
.8
14
.8
o
di
ffe
re
nc
e
in
du
ra
tio
n
of
cl
op
id
og
re
l
$1
22
(
$7
96
to
$1
,0
28
)
12
.2
$9
97
96
.9
40
.5
$1
0,
18
3
82
.9
40
.5
ul
at
io
n:
cl
in
ic
al
F/
U
ri
m
ar
y
an
al
ys
is
†
$9
7
(
$1
,3
76
to
$1
,4
98
)
12
.7
$7
60
90
.0
46
.0
$5
,1
05
76
.3
46
.0
o
di
ffe
re
nc
e
in
du
ra
tio
n
of
cl
op
id
og
re
l

$3
53
(
$1
,8
26
to
$1
,0
48
)
12
.7
D
om
in
an
t
96
.5
66
.8
D
om
in
an
t
89
.3
66
.8
rc
en
ta
ge
s
an
d
co
nfi
de
nc
e
in
te
rv
al
s
ar
e
ba
se
d
on
5,
00
0
bo
ot
st
ra
p
si
m
ul
at
io
ns
of
tr
ia
lr
es
ul
ts
.†
P
ri
m
ar
y
an
al
ys
is

6
m
on
th
s
of
du
al
an
tip
la
te
le
t
th
er
ap
y
in
pa
cl
ita
xe
l-
el
ut
in
g
st
en
t
gr
ou
p
ve
rs
us
1
m
on
th
in
co
nt
ro
lg
ro
up
.
/E

co
st
-e
ffe
ct
iv
en
es
s;
C
I

co
nfi
de
nc
e
in
te
rv
al
;F
/U

fo
llo
w
-u
p;
R
ep
R
ev

re
pe
at
re
va
sc
ul
ar
iz
at
io
n;
Q
A
L
Y

qu
al
ity
-a
dj
us
te
d
lif
e
ye
ar
.
258 Bakhai et al. JACC Vol. 48, No. 2, 2006
Cost Effectiveness of Paclitaxel-Eluting Stents July 18, 2006:253–61Our findings were also sensitive to the cost of hospital-
zation for repeat revascularization and to the analytic
erspective. If repeat revascularization costs were, on aver-
ge, 48% lower than observed in our study, the cost-
ffectiveness ratio for PES would increase to $10,000 per
epeat revascularization avoided. On the other hand, if
epeat revascularization costs were 43% higher than we
bserved, initial PES implantation would be a cost-saving
trategy. When examined from the perspective of the
edicare system, aggregate 1-year costs were slightly lower
or PES than for BMS ($18,818 vs. $19,045; 95% CI for
ifference $1,374 less to $919 more). In contrast, from the
ospital perspective, net profit (i.e., revenue-cost) per pa-
ient was actually lower with PES than BMS ($6,605 vs.
7,064; 95% CI $1,120 less to $201 more).
ISCUSSION
his is the first prospective economic evaluation of coronary
ES within the U.S. health care system. Using individual
atient-level data from the TAXUS-IV trial, we found that
se of PES increased initial hospital costs by more than
2,000 per patient compared with conventional BMS im-
lantation, driven predominantly by the higher acquisition
ost of the PES. Nonetheless, over the 1-year follow-up
igure 1. Cumulative follow-up costs for the paclitaxel and control stent
roups for the overall trial population (A) and the subgroup assigned to
linical follow-up alone (B). Mean cost differences at 6, 9, and 12 months
re indicated in the boxes.eriod, use of PES was associated with significant reduc- Ta
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July 18, 2006:253–61 Cost Effectiveness of Paclitaxel-Eluting Stentsions in a variety of morbid events, including rehospitaliza-
ion (12 fewer events per 100 patients treated), repeat PCI
10 fewer events per 100 patients treated), and bypass
urgery (2 fewer events per 100 patients treated). In addition
o these clinical benefits, use of PES was associated with a
eduction in follow-up medical care costs of $1,500 per
atient.
Although these cost savings were insufficient to fully
ffset the higher initial treatment costs, the overall results
f our economic analysis nonetheless suggest that use of
ES may be reasonably cost-effective from a societal
erspective over a broad range of patient and lesion
haracteristics. Indeed, the incremental cost-effectiveness
atio of $4,700 per TVR event avoided for PES compares
avorably with the cost effectiveness of several other
evices that have been shown to reduce coronary reste-
igure 2. Cumulative distribution plot of the incremental cost-
ffectiveness ratio for paclitaxel-eluting stent compared with bare-metal
tent based on bootstrap analysis of the primary TAXUS-IV trial results
mong the overall study population (A) and the subgroup assigned to
linical follow-up alone (B). As indicated by the arrow, 86% of the
esulting cost-effectiveness ratios were $10,000 per target vessel revascu-
arization event avoided for the overall population, and 90% were less than
his threshold for the clinical follow-up cohort.osis, including BMS (vs. balloon angioplasty) (9,24) and tascular brachytherapy (22). Moreover, this cost-
ffectiveness ratio is also substantially lower than empir-
cally derived willingness-to-pay thresholds for PCI pa-
ients in the U.S. (25). The relative attractiveness of PES
s also corroborated by our cost-utility analysis, which
howed that for the overall TAXUS-IV population, the
ost-utility ratio for PES implantation was $50,000/
ALY gained—a commonly cited benchmark for the
.S. health care system (26).
omparison with previous studies. The only previous
tudy to examine the cost effectiveness of DES in the U.S.
ealth care system was performed alongside the SIRIUS
Sirolimus-Eluting Balloon Expandable Stent in the Treat-
ent of Patients with De Novo Native Coronary Lesions)
rial (5). In that study, use of SES compared with BMS was
ssociated with a net 1-year cost of $300 per patient and
reduction of 19 revascularization events per 100 patients
reated, with an incremental cost-effectiveness ratio of
1,650 per repeat revascularization avoided and $27,540/
ALY gained. It is important to recognize that even
hough both the TAXUS-IV and the SIRIUS trials com-
ared DES with an approved BMS, the ability to perform
eaningful indirect economic comparisons between the 2
rials is limited. In particular, the BMS used in each study
iffered in a number of important characteristics, including
tent geometry and strut thickness. Moreover, the 1-year
ate of TVR in the control population differed substantially
etween the 2 studies. Thus, it is not possible to directly
ompare the cost effectiveness of these alternative DES
esigns based on the current data. Ongoing studies involv-
ng direct comparisons of alternative DES systems may be
elpful in this regard.
An additional difference between the 2 trials was the
uration of dual antiplatelet therapy after stent implanta-
ion. In the SIRIUS trial, patients in the DES arm were
equired to receive 3 months of dual antiplatelet therapy,
hereas 6 months of dual antiplatelet therapy were pre-
cribed in the TAXUS-IV trial. In both trials, the excess
uration of dual antiplatelet therapy (at a cost of $100/
onth) accounted for nearly all of the net cost of DES
lacement at 1 year. Thus, if one were to assume that all
atients would receive 1 year of dual antiplatelet therapy after
tent placement (as supported by the CREDO [Clopidogrel
or the Reduction of Events During Observation] trial) (27),
se of both SES and PES would have been nearly cost neutral
n their respective trials. On the other hand, if one assumes
hat standard practice is to prescribe only 1 month of dual
ntiplatelet therapy after BMS implantation, the shorter
uration of therapy prescribed with the SES may represent
relative economic advantage of this platform.
In addition to extending our previous findings regarding
he cost effectiveness of SES to a second DES system, the
urrent study adds to our understanding of the optimal
pplication of these devices in several ways. Stratified
nalyses of the overall trial population show that implanta-
ion of PES is cost saving for several patient subgroups,
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Cost Effectiveness of Paclitaxel-Eluting Stents July 18, 2006:253–61ncluding patients with diabetes and lesions located in
essels with a reference diameter 2.5 mm. These findings
re not surprising given that both smaller reference vessel
iameters and diabetes are associated with higher rates of
linical and angiographic restenosis after BMS implantation
28). On the other hand, for patients with reference vessel
iameters 3.0 mm, our analysis suggests that even though
se of PES results in significant reductions in restenosis, at
urrent stent prices the cost-effectiveness ratio exceeds
20,000 per repeat revascularization avoided. Thus, in
ealth care systems with constrained resources, use of PES
or such patients might be considered economically unat-
ractive at current stent prices.
Finally and most importantly, this study is the first to
pecifically evaluate the cost effectiveness of DES among
atients undergoing clinical follow-up alone. Several previ-
us studies have shown that rates of repeat revascularization
re increased substantially when patients are subject to
andatory angiographic follow-up because of the “oculo-
tenotic reflex” (9,10). Thus, economic analyses derived
rom clinical trials that incorporate angiographic follow-up
n a high proportion of patients may overestimate both the
linical and the economic benefits of DES compared with
hose that would be observed in routine clinical practice. In
he TAXUS-IV trial, analysis of the prespecified subgroup
ssigned to clinical follow-up alone showed a net 1-year cost
f $97 per patient for the PES group with a highly favorable
ncremental cost-effectiveness ratio of $1,000 per TVR
voided. It is interesting to note that the 1-year follow-up cost
ffset with PES in the nonangiographic cohort was greater
han that observed in the angiographic cohort ($1,894 per
atient vs. $1,104 per patient). It is possible that these
omewhat counterintuitive results reflect the fact that repeat
evascularization procedures in the nonangiographic cohort
ere more challenging and resource-intensive compared with
igure 3. Subgroup analyses of rates of target vessel revascularization (TV
tent groups along with the associated cost-effectiveness ratios for paclitaxe
hose subgroups for which PES implantation was economically dominan
escending coronary artery.hose procedures driven by angiographic findings alone. Re- eardless of the underlying mechanism, the fact that the
ost-effectiveness ratio remained $10,000 per TVR avoided
n more than 90% of bootstrap replicates provides substantial
onfidence in the cost effectiveness of PES for real-world PCI
atients similar to the TAXUS-IV trial population.
tudy limitations. Our study has several important limi-
ations. Given the multicenter nature of the trial, it was not
ossible to obtain cost data from the internal accounting
ystems of each participating center. Consequently, our
stimates of catheterization laboratory costs (other than
evices and medications) were based on data from a single
ospital. We do not believe that this approach detracts
ubstantially from our findings, however, because most
rocedural costs were estimated using national average
rice-weights, and the remainder accounted for only 13% of
otal costs at 1 year. In addition, we only collected detailed
illing data on a subset of study participants. It is unlikely
hat we substantially underestimated hospital costs for the
ther participants, however, because our imputation model
ccounted for both ICU and non-ICU length of stay—the
ajor determinants of hospital cost.
As with any clinical trial, the results of our study should
e considered specific to the trial population and may not be
pplicable to the full spectrum of PCI patients. In particular,
ur findings cannot be extrapolated directly to populations
or whom the incremental cost of DES would be substan-
ially greater than in the TAXUS-IV trial, such as very long
esions or patients undergoing multivessel revascularization.
oreover, our analysis was limited to a 1-year follow-up
eriod. If future studies show a significant excess of late events
either stent thrombosis or restenosis) with PES, the cost
ffectiveness of PES would be less favorable than suggested by
ur current data. Finally, quality of life data were not directly
vailable in this trial. As a result, our cost-utility analysis was
ased on extrapolated utility weights from U.S. stent patients
d 1-year medical care cost differences between the paclitaxel and control
ing stent (PES) versus bare-metal stent implantation. Dominant indicates
, lower overall costs and better clinical outcomes). LAD  left anteriorR) an
l-elutnrolled in a previous study (17). In this regard, it is reassuring
t
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estenosis were comparable to those recently reported from a
imilar analysis of Canadian patients (29).
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